NCT03617081View on ClinicalTrials.gov

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

December 13, 2018

Study Completion Date

December 13, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0113-2023

Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.

DRUG

Placebo (NNC0113-2023)

Participants will receive NNC0174-0833 matched placebo orally.

Trial Locations (1)

78209

Novo Nordisk Investigational Site, San Antonio

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY